Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
November 05, 2019 02:00 ET
|
Verona Pharma plc
Reported positive Phase 2 data with dry powder inhaler formulation Post period end, completed enrollment in Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator LONDON,...
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
October 29, 2019 03:00 ET
|
Verona Pharma plc
LONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
October 17, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized...
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
October 15, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
September 19, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...
Holding(s) in Company TR-1: Standard form for notification of major holdings
September 09, 2019 09:33 ET
|
Verona Pharma plc
LONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma plc: PDMR Dealing
August 09, 2019 04:35 ET
|
Verona Pharma plc
LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
August 06, 2019 02:00 ET
|
Verona Pharma plc
Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator Initiated first Phase 2 study with metered-dose inhaler formulation Post-period end reported positive...
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
August 05, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data...